| Dr Keith Stephenson, MD | |
|
2310 Kuhio Ave Ste 223, Honolulu, HI 96815-2950 | |
| (808) 674-1600 | |
| (808) 943-1116 |
| Full Name | Dr Keith Stephenson |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 2310 Kuhio Ave Ste 223, Honolulu, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154547768 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | MD-7206 (Hawaii) | Primary |
| Entity Name | Keith Stephenson Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619439890 PECOS PAC ID: 1254708985 Enrollment ID: O20221109000314 |
News Archive
A ketogenic diet - which provides 99% of calories from fat and only 1% from carbohydrates - produces health benefits in the short term, but negative effects after about a week, Yale researchers found in a study of mice.
Researchers have shown for the first time how neurons in the SCN are connected to each other, shedding light on this vital area of the brain. Understanding this structure — and how it responds to disruption — is important for tackling illnesses like diabetes and posttraumatic stress disorder. The scientists have also found that disruption to these rhythms such as shifts in work schedules or blue light exposure at night can negatively impact overall health.
A new test could help identify and treat individuals at risk of developing potentially deadly calcium deposits in their tissues and blood vessels, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. Heart disease is the number one killer of patients with chronic kidney disease (CKD), and vascular calcification is thought to play a major role.
RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Keith Stephenson, MD 1201 Wilder Ave Apt 2906, Honolulu, HI 96822-3151 Ph: (808) 674-1600 | Dr Keith Stephenson, MD 2310 Kuhio Ave Ste 223, Honolulu, HI 96815-2950 Ph: (808) 674-1600 |
News Archive
A ketogenic diet - which provides 99% of calories from fat and only 1% from carbohydrates - produces health benefits in the short term, but negative effects after about a week, Yale researchers found in a study of mice.
Researchers have shown for the first time how neurons in the SCN are connected to each other, shedding light on this vital area of the brain. Understanding this structure — and how it responds to disruption — is important for tackling illnesses like diabetes and posttraumatic stress disorder. The scientists have also found that disruption to these rhythms such as shifts in work schedules or blue light exposure at night can negatively impact overall health.
A new test could help identify and treat individuals at risk of developing potentially deadly calcium deposits in their tissues and blood vessels, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. Heart disease is the number one killer of patients with chronic kidney disease (CKD), and vascular calcification is thought to play a major role.
RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
› Verified 5 days ago
Dr. Zhelah B Kayce, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 1009 Kapiolani Blvd, #4607, Honolulu, HI 96814 Phone: 808-744-6979 | |
Dr. James S. Barahal, M.D. General Practice Medicare: May Accept Medicare Assignments Practice Location: 120 Kaiulani Ave, Lobby Level, Honolulu, HI 96815 Phone: 808-971-6000 Fax: 808-971-6042 | |
Brandon Osamu Takase, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 550 S Beretania St Ste 300, Honolulu, HI 96813 Phone: 808-686-4620 Fax: 808-686-2125 | |
Dr. Jamie Leigh Malone, D.O General Practice Medicare: Medicare Enrolled Practice Location: 1010 Pensacola St, Honolulu, HI 96814 Phone: 808-432-2000 | |
Dr. William Fruean, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 2225 N School St, Suite 203, Honolulu, HI 96819 Phone: 808-845-9754 Fax: 808-845-9755 | |
Dr. Alex Wah Hin Yeung, MBBS General Practice Medicare: Medicare Enrolled Practice Location: 1329 Lusitana St Ste 609, Honolulu, HI 96813 Phone: 808-892-0929 |